Biotech News

NEXGEL New Strategic Partner, Sequence LifeScience™, Leads Financing with $5.5 Million to Complete Acquisition of Celularity Degenerative Disease Segment

NEXGEL (NXGL)NEXGEL2026-04-21 13:00 ESTFinancing

NXGL (NXGL) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is nxgl.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

NEXGEL

NexGel is a hydrogel and wound-care company focused on advanced dressings and delivery materials. Its business is centered on materials science rather than therapeutics or classic biotech.

Recent company news

NXGLNEXGEL2026-06-04 13:00 EST

NEXGEL to Present at Planet MicroCap Conference Las Vegas on June 16th –18th

NXGLNEXGEL2026-05-19 13:00 EST

NEXGEL Reports Positive Data from Randomized Single-Center IRB Study to Evaluate the Effectiveness and Safety of a Hydrogel Laser Treatment Patch in Laser Hair Removal with a 95.6% Reduction in Plume Concentration

NXGLNEXGEL2026-05-13 12:30 EST

Stock data

Close: 0.34 USD
Market cap: 5.31M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States

NEXGEL New Strategic Partner, Sequence LifeScience™, Leads Financing with $5.5 Million to Complete Acquisition of Celularity Degenerative Disease Segment

Related news

NEXGEL Appoints Brian Kieser and Kevin Harris from New Strategic Partner, Sequence LifeScience™, to Board of Directors

NEXGEL Moves Forward Shareholder Update Call to Discuss Celularity Transaction on April 21st at 4:30 P.M. ET